Opendata, web and dolomites
  1. home
  2. trasparenza
  3. open h2020
  4. hyposkin

HypoSkin SIGNED

Unique breakthrough ex vivo human skin model to predict efficacy and toxicity of subcutaneous drugs

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0
 Outcomes and results

 HypoSkin project word cloud

Explore the words cloud of the HypoSkin project. It provides you a very rough idea of what is the project "HypoSkin" about.

pilot    world    hyposkin    worldwide    toulouse    first    ex    sabatier    genoskin    vivo    money    pharmaceuticals    disruptive    framework    care    110    standardized    industrialise    home    limits    scientific    provides    skin    improves    biopsies    administration    security    7    reduces    device    accurate    turnover    cagr    global    local    view    qualify    patient    cheaper    decrease    national    sales    2017    fat    injection    causing    faster    models    34    sme    alternative    sharpen    vitro    reliably    paul    secure    experiment    customers    deepen    tissue    instrument    model    issue    founded    off    inadequate    88    regulatory    health    university    french    risks    companies    payed    sharp    biological    center    absence    drug    subcutaneous    replace    kit    effect    predict    market    time    1b    parenteral    leads    times    700k    reference    company    innovation    permits    living    trials    innovative    ready    life    confirmed    containing    route    human    medical    quality    save    feasibility    animal    spin    2011    attrition    2024    clinical    plans    jobs    complete   

Project "HypoSkin" data sheet

The following table provides information about the project.

Coordinator		 GENOSKIN SAS 

Organization address
address: CENTRE PIERRE POTIER, 1 PLACE PIERRE POTIER
city: TOULOUSE
postcode: 31100
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.
 Coordinator Country France [FR]
 Project website http://www.genoskin.com
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2018
 Duration (year-month-day) from 2018-06-01   to  2018-11-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    GENOSKIN SAS FR (TOULOUSE) coordinator 50˙000.00

Map

 Project objective

Subcutaneous injection drug market is highly increasing (CAGR of 7%) and is view as a viable alternative route for parenteral drug administration because it enables at-home injection, improves quality of life and reduces health care costs. However, the absence of accurate biological model to predict the effect of drug injection in the subcutaneous tissue limits their development. That issue leads to 88% of drug attrition causing a loss of more than €1B per developed drug and a sharp decrease of patient security during clinical trials.

HypoSkin is the first and unique in vitro standardized and ready-to-use testing kit containing living ex vivo human skin biopsies with subcutaneous fat, allowing pharmaceuticals to highly reliably predict local human’s response to the injection of a drug or a medical device. This disruptive innovation permits Hyposkin’s customers to save time and money (10 times faster and 5 times cheaper than animal experiment, confirmed in the on-going payed pilot test) as well as secure the development of their products before clinical trials. HypoSkin will become worldwide reference method to replace inadequate animal testing currently used today.

HypoSkin model is developed by Genoskin an innovative French company, founded in 2011 as a spin-off of the French National Center for Scientific Research and the Paul Sabatier University in Toulouse. Genoskin provides other human-skin alternative models to pharmaceuticals companies all over the world leading to sales of €700K in 2017.

The SME Instrument project will allow the company to improve, qualify and industrialise HypoSkin. To accomplish this goal Genoskin will complete a feasibility study to further analyse risks and cost of scale-up, the European regulatory framework and will deepen and sharpen the global subcutaneous injection market. Genoskin plans to lead the European and global alternative method market with an estimated turnover of € 34 M by 2024, and 110 new European and worldwide jobs.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "HYPOSKIN" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "HYPOSKIN" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

Colourganisms (2020)

Microbial production of custom-made, pure and sustainable anthocyanins

Read More  

TAPPXSSAI (2019)

Development of a system for automatic ad insertion into on-demand streaming video to provide new monetization mechanisms to the media industry

Read More  

BeatsDigTherapeutics (2019)

Project SCALE: Tailored Digital Therapeutics for Neurological and Brain Disorders

Read More